Compare Peptides
Select any two compounds for a side-by-side comparison of mechanism, uses, risks, and FDA regulatory status.
Popular comparisons
A once-weekly GLP-1 receptor agonist FDA-approved for type 2 diabetes and cardiovascular risk reduction. Developed by Eli Lilly as a predecessor to tirzepatide. One of the most prescribed GLP-1 agonists globally.
The first widely used GLP-1 receptor agonist for weight management, developed by Novo Nordisk. Predates semaglutide and tirzepatide. While largely superseded by newer agents for weight loss, it remains FDA-approved and widely prescribed, particularly for patients who tolerate it well or have established insurance coverage.
A GLP-1 analog fused to a modified IgG4 Fc fragment, extending its half-life to approximately 5 days. Activates GLP-1 receptors to stimulate insulin secretion, suppress glucagon, slow gastric emptying, and reduce appetite.
Activates GLP-1 receptors, stimulating insulin secretion, suppressing glucagon, slowing gastric emptying, and reducing appetite. Requires daily injection due to a shorter half-life than semaglutide. The daily dosing schedule is both a limitation and, for some patients, a feature — easier to stop quickly if side effects occur.
- Type 2 diabetes
- Cardiovascular risk reduction
- Moderate weight loss
- Blood sugar regulation
- Weight management (FDA-approved as Saxenda)
- Type 2 diabetes (FDA-approved as Victoza)
- Cardiovascular risk reduction
- GI side effects (nausea, diarrhea, vomiting)
- Pancreatitis (rare)
- Thyroid C-cell tumors (animal studies)
- Injection site reactions
- Hypoglycemia when combined with insulin
- Nausea and vomiting (common, especially during titration)
- Pancreatitis risk
- Gallbladder disease
- Potential thyroid C-cell tumor risk (animal data)
- Daily injection burden vs. weekly alternatives
FDA-approved as Trulicity (2014) for type 2 diabetes and cardiovascular risk reduction (REWIND trial). Once-weekly injection via single-dose pen. One of the top-selling GLP-1 drugs globally.
FDA-approved as Victoza (type 2 diabetes, 2010) and Saxenda (weight management, 2014). The LEADER trial demonstrated cardiovascular risk reduction in diabetic patients. Largely superseded by semaglutide and tirzepatide for new prescriptions due to superior efficacy and weekly dosing, but remains a valid option with established long-term safety data.
This comparison is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any peptide therapy.